Source study found

Story checked

Metformin in pregnancy does not raise developmental risk in children (opens in a new tab)

news-medical.net · 2026-10-07

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Metformin in pregnancy does not raise developmental risk in children

news-medical.net · 2026-10-07

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

3 supported
2 not covered

Open claim evidence

The source study

Metformin Exposure in Pregnancy and Childhood Developmental Outcomes.

JAMA Network Open · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe article says sensitivity analyses were similar, including analyses limited to pregnancies complicated by gestational diabetes or type 2 diabetes, excluding children with special educational needs or incomplete outcome data, and restricting exposure to the first trimester.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not document the claimed sensitivity analyses, diabetes-restricted analyses, exclusions for special educational needs or incomplete outcome data, or first-trimester exposure restriction. These may be in the full paper, but they are not verifiable from the abstract-depth profile.

Claim 2 of 5Not coveredBecause the study was observational, the article notes it could not rule out residual confounding and lacked information on metformin dose, actual ingestion, and specific indication for treatment.View evidenceHide evidence

Why this verdict

The profile supports that the study was observational and that exposure was based on prescription dispensation, which bears on actual ingestion. However, the supplied abstract-depth profile does not list residual confounding, lack of dose information, actual ingestion, or indication for treatment as paper limitations. The claim is plausible for an observational medication-dispensing study but is not fully verifiable at this evidence depth.

Study evidence

Antenatal metformin prescription dispensation was not associated with developmental vulnerability at school entry after adjustment.adjusted RR 0.97 (95% CI 0.74–1.29)

“This cohort study used population-level pregnancy and birth data from January 1, 2009, to December 31, 2020, linked with the Australian Early Development Census (AEDC)”

Study evidence

Metformin exposure in pregnancy was not associated with altered risk in any of the five individual AEDC developmental domains at school entry after adjustment.

“across any of the individual developmental domains”

Claim 3 of 5SupportedA recent study published in JAMA Network Open examined whether metformin exposure during pregnancy was associated with developmental vulnerabilities in children during the first year of full-time school.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the JAMA Network Open study examined whether antenatal metformin prescription during pregnancy was associated with developmental vulnerability at school entry, including AEDC-based developmental outcomes at age 4–6 years.

Study evidence

Antenatal metformin prescription dispensation was not associated with developmental vulnerability at school entry after adjustment.adjusted RR 0.97 (95% CI 0.74–1.29)

“This cohort study used population-level pregnancy and birth data from January 1, 2009, to December 31, 2020, linked with the Australian Early Development Census (AEDC)”

Study evidence

Metformin exposure in pregnancy was not associated with altered risk in any of the five individual AEDC developmental domains at school entry after adjustment.

“across any of the individual developmental domains”

Claim 4 of 5SupportedResearchers conducted a cohort study of singleton births in Victoria, Australia, linking pregnancy, birth, medication, and developmental data to assess metformin exposure from the last normal menstrual period to birth.View evidenceHide evidence

Why this verdict

The profile supports a population-based linked cohort of singleton births in Victoria, Australia, using pregnancy and birth data linked to AEDC developmental outcomes, with exposure as metformin prescription dispensation during pregnancy. The profile states exposure as dispensation during pregnancy rather than explicitly as 'from the last normal menstrual period to birth,' but the claim is broadly consistent with the abstract-level methods.

Study evidence

Antenatal metformin prescription dispensation was not associated with developmental vulnerability at school entry after adjustment.adjusted RR 0.97 (95% CI 0.74–1.29)

“This cohort study used population-level pregnancy and birth data from January 1, 2009, to December 31, 2020, linked with the Australian Early Development Census (AEDC)”

Claim 5 of 5SupportedAmong 177,409 children with linked developmental outcome data, 1,095 had antenatal metformin exposure; after adjustment, metformin exposure was not associated with developmental vulnerability or any of the five individual AEDC domains.View evidenceHide evidence

As stated18.2% vs 13.9% unadjusted; no association after adjustment

Why this verdict

The profile reports 177,409 children with linked AEDC outcomes, 1,095 exposed to antenatal metformin, crude developmental vulnerability of 18.2% vs 13.9%, and no adjusted association with developmental vulnerability, with adjusted RR 0.97 (95% CI 0.74–1.29). It also supports no association across individual AEDC domains, although the abstract-level profile provides that domain result qualitatively rather than with domain-specific estimates.

Study evidence

Antenatal metformin prescription dispensation was not associated with developmental vulnerability at school entry after adjustment.adjusted RR 0.97 (95% CI 0.74–1.29)

“This cohort study used population-level pregnancy and birth data from January 1, 2009, to December 31, 2020, linked with the Australian Early Development Census (AEDC)”

Study evidence

Metformin exposure in pregnancy was not associated with altered risk in any of the five individual AEDC developmental domains at school entry after adjustment.

“across any of the individual developmental domains”

Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

9 things the story did carry across

Primary study question: whether antenatal metformin prescription during pregnancy is associated with offspring developmental vulnerability at school entry in a Victorian population-linked cohort.
Study design and data source: population-based linked cohort of singleton births in Victoria, Australia, 2009–2020, with pregnancy/birth data linked to AEDC outcomes at age 4–6 years.
Exposure definition: metformin prescription dispensation during pregnancy, not necessarily confirmed ingestion.
Primary outcome definition: developmental vulnerability defined as scoring below the 10th percentile in at least 2 of 5 AEDC domains at school entry.
Main adjusted result: metformin exposure was not associated with developmental vulnerability after IPTW plus regression adjustment; adjusted RR 0.97, 95% CI 0.74–1.29, despite higher crude vulnerability in exposed children.
Domain-specific result: no association was reported across any of the five individual AEDC domains.
Exposure sample size was relatively small compared with the linked cohort: 1,095 exposed children among 177,409 with linked AEDC data.
Outcome timing limitation: outcomes were assessed at a single early childhood time point, school entry age 4–6 years.
Observational design: the cohort can support adjusted associations but not definitive causal conclusions.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate whether antenatal metformin prescription during pregnancy is associated with offspring developmental vulnerability at school entry (age 4-6 years) in a population-linked cohort.population-based linked cohortExpand

In plain English

Population-based linked-cohort study (Victoria, Australia, 2009–2020) evaluating whether antenatal metformin prescription dispensation is associated with developmental vulnerability at school entry (AEDC assessment, age 4–6). Using IPTW combined with regression adjustment, metformin exposure was not associated with developmental vulnerability (adjusted RR 0.97, 95% CI 0.74–1.29).

Key findings

Antenatal metformin prescription dispensation was not associated with developmental vulnerability at school entry after adjustment.adjusted RR 0.97 (95% CI 0.74–1.29)

“This cohort study used population-level pregnancy and birth data from January 1, 2009, to December 31, 2020, linked with the Australian Early Development Census (AEDC)”

2secondary dataAssess whether any association differs across individual developmental domains of the Australian Early Development Census (AEDC).Population-based linked cohort; IPTW with regression adjustmentExpand

In plain English

Within the same population-based Victorian birth cohort linked to AEDC assessments at school entry (age 4–6 years), metformin dispensation in pregnancy was not associated with altered risk across any of the five individual AEDC developmental domains (physical health and well-being; social competence; emotional maturity; school-based language and cognitive skills; communication skills and general knowledge) after applying inverse probability of treatment weighting with regression adjustment.

Key findings

Metformin exposure in pregnancy was not associated with altered risk in any of the five individual AEDC developmental domains at school entry after adjustment.

“across any of the individual developmental domains”

What this piece can’t prove

Relatively small number of exposed children in the linked sample (1,095 exposed among 177,409 with AEDC data).
Outcomes assessed only at school entry (age 4–6 years) in the reported analysis.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer